Aurealis Therapeutics

Aurealis Therapeutics stands with DFU patients on World Diabetes Day 💙 🌍   Today, on World Diabetes Day, we stand in solidarity with the 537 million people living with diabetes worldwide. At Aurealis Therapeutics, we are deeply committed to addressing the severe complications of diabetes, particularly diabetic foot ulcers (DFUs)—a life-threatening condition that affects millions. AUP-16, our innovative multi-target cell and gene therapy, aims to bring hope and healing to DFU patients. AUP-16 Phase 1 DFU clinical study was completed with 83% of the patients achieving complete healing; AUP-16 Phase 2 clinical study is ongoing and recently reached its last patient last treatment milestone. On this day, let’s raise awareness about the burden of diabetes and highlight our commitment to developing solutions that not only promote wound healing but also improve the quality of life for those living with this complex, chronic condition. Together, we can work toward a healthier future.   🔗 Scientific article on AUP-16 Phase 1 DFU clinical trial: https://lnkd.in/grsVN-kh 🔗 AUP-16 Phase 2 DFU clinical trial – Last Patient Last Treatment milestone: https://lnkd.in/gT4Nir45 #WorldDiabetesDay #DiabetesAwareness #DiabeticFootUlcers #ChronicWounds #GeneTherapy #CellTherapy #AurealisTherapeutics

Aurealis Therapeutics announces the successful completion of an CHF 8 million funding round from our existing investors and shareholders! This funding will support the achievement of two important milestones: 🔹 Completing the Phase 2 clinical trials of AUP-16 for chronic wounds, such as Diabetic Foot Ulcers. 🔹 Accelerating preclinical and CMC development of AUP-55 for cancers, including ovarian and bladder cancer. With our multi-targeting cell and gene therapy platform, we’re tackling some of the most complex and unmet medical needs in chronic wounds and deadly cancers. Together with our partners, we remain committed to developing solutions that transform the lives of patients worldwide. 🌍   🔗Read the press release: https://lnkd.in/gUDZ3fni #AurealisTherapeutics #Biotech #CellTherapy #GeneTherapy #ChronicWounds #CancerTherapy #Innovation #FundingRound

Aurealis Therapeutics is proud to announce the publication of AUP-16 peer-reviewed clinical paper summarizing Phase-1 study results in the renowned medical journal "𝐓𝐡𝐞𝐫𝐚𝐩𝐞𝐮𝐭𝐢𝐜 𝐀𝐝𝐯𝐚𝐧𝐜𝐞𝐬 𝐢𝐧 𝐄𝐧𝐝𝐨𝐜𝐫𝐢𝐧𝐨𝐥𝐨𝐠𝐲 𝐚𝐧𝐝 𝐌𝐞𝐭𝐚𝐛𝐨𝐥𝐢𝐬𝐦". AUP-16 is our leading multi-target cell and gene therapy, designed to address the unmet medical need of non-healing diabetic foot ulcers (nhDFUs). We are very excited to share the publication of our Phase-1 data with AUP-16 which highlights its promising potential: 🔹 83% complete wound healing observed in patients who received the recommended Phase 2 dose. 🔹 Well-tolerated treatment with no serious adverse reactions reported. 🔹 No recurrence of healed wounds during the 12-month follow-up. This publication brings the findings of our Phase-1 clinical trial to the global medical community and shows AUP-16's ability to create a meaningful difference in the lives of patients suffering from nhDFUs. Recently, AUP-16 completed Last Patient Last Treatment milestone in ongoing DIAMEND Phase 2 clinical study in nhDFUs. 🔗 Read the publication: https://lnkd.in/gjRrHd3v 🔗 Read the press release: https://lnkd.in/gak-d_Yv #AurealisTherapeutics #AUP16 #GeneTherapy #CellTherapy #ChronicWounds #DiabeticFootUlcers #Biotech #AUP16 #MedicalResearch Christoph Schindler Jacek Mikosiński Pawel Mikosiński Hanna-Riikka Kärkkäinen Mirka Sanio Jere Kurkipuro Igor Mierau Wesley Smith Aki Vartiainen Laurent Decory Dirk Weber Thomas Wirth Juha Yrjänheikki Sebastian Schellong Haritha Samaranayake Sage

Our team at Aurealis Therapeutics is ready for BIO-Europe 2024, will we see you there? We’re excited to be heading to Stockholm from November 4-6, where our CEO, Juha Yrjänheikki, and COO, Laurent Decory, will represent Aurealis Therapeutics at BIO-Europe – Europe’s premier biotech partnering event!   Join us to connect, collaborate, and learn more about our innovative multi-target cell and gene therapy platform, including the latest updates on AUP-16, our leading asset for chronic wound treatment, which recently reached the "Last Patient Last Treatment" milestone in its DIAMEND Phase 2 DFU study.   We are looking forward to meaningful conversations with potential investors and partners. We hope to see you there! 🚀   🔗 Book a meeting: https://lnkd.in/dSh2WhAN 🔗 Register here: https://lnkd.in/dnuNZ2D 🔗 Contact us: https://lnkd.in/gcqQbEKp     #AurealisTherapeutics #BIOEUROPE #Biotech #CellTherapy #GeneTherapy #Innovation #Partnerships #Investors #Stockholm2024

Aurealis Therapeutics is excited to announce that the last patient in its DIAMEND AUP-16 Phase 2 clinical trial on non-healing DFUs has completed treatment. 🎉 Reaching this milestone marks the end of the treatment phase and the start of a 12-month follow-up period. Diabetic Foot Ulcers (DFUs) are a serious condition affecting millions, and we are proud to be one step closer to delivering an innovative, multi-target gene therapy for these non-healing chronic wounds. 𝐓𝐢𝐦𝐞𝐥𝐢𝐧𝐞 𝐇𝐢𝐠𝐡𝐥𝐢𝐠𝐡𝐭𝐬 𝐨𝐟 𝐃𝐈𝐀𝐌𝐄𝐍𝐃 𝐬𝐭𝐮𝐝𝐲: 🔹Study Approval: May 2023 🔹First Patient Treated: August 2023 🔹Recruitment Completed: August 2024 🔹Last Treatment: October 2024 A big thank you to the dedicated clinical teams, our partners, and the patients who made this study possible! 🔗 Read the full press release: https://lnkd.in/gT4Nir45 #ClinicalTrial #LPLT #Innovation #Biotech #DiabeticFootUlcers #GeneTherapy #AurealisTherapeutics #DIAMENDStudy

Aurealis Therapeutics is proud to sponsor the EWMA Diabetic Foot Committee! We are excited to support the EWMA Diabetic Foot Committee, established in 2023, which plays a key role in advancing diabetic foot ulcer (DFU) care across Europe. Its mission to implement the IWGDF guidelines and promote research aligns perfectly with our focus on chronic wound management and innovative therapies. At Aurealis, we are dedicated to advancing solutions for diabetic foot ulcers with AUP-16, our multi-target cell and gene therapy currently in Phase 2 clinical trial. Supporting the EWMA Diabetic Foot Committee allows us to contribute to the global effort to improve DFU outcomes and connect with specialists committed to making a difference. 📅 The EWMA conference is an event we never miss! It provides a fantastic space for sharing knowledge and advancing the treatment of diabetic foot ulcers. The next conference will take place in Barcelona in March 2025. Curious to learn more? 🔗 Read our article: https://lnkd.in/gsM-Ht9G 🔗 Explore the EWMA Diabetic Foot Committee: https://lnkd.in/gbJx6K4n   #EWMA #DiabeticFootCare #ChronicWounds #Biotech #Innovation #AurealisTherapeutics #AUP16 #DiabeticFootCommittee EWMA • European Wound Management Association EWMA Innovation Alliance Juha Yrjänheikki Laurent Decory Maija Rusi Haritha Samaranayake Roger Meier Silvio Inderbitzin Jean De Gunzburg Tuomo Pätsi Igor Mierau Jere Kurkipuro Hanna-Riikka Kärkkäinen Mirka Sanio Jade Jimenez Magdalena Annersten Gershater Joachim Dissemond Isoherranen Kirsi David Armstrong Alberto Piaggesi Jan Apelqvist Valentina Dini Arkadiusz Jawień

Aurealis Therapeutics will be participating at BIO-EUROPE 2024 in Stockholm, Sweden! 🇸🇪 We are excited to announce our participation at BIO-EUROPE from 4-6 November in Stockholm, Sweden – just under four weeks from now. Our CEO, Juha Yrjänheikki, and COO, Laurent Decory, will both be attending the event and are looking forward to connecting with fellow industry leaders, investors, and potential partners to explore new collaboration opportunities. Curious about our latest clinical progress and investment opportunities? We will be happy to share insights and discuss potential paths for collaboration. BIO-EUROPE, Europe’s leading partnering event, offers a fantastic platform to build connections and establish long-term partnerships that help drive innovation in biotech. If you are attending, feel free to reach out – see you in Stockholm! 🔗 Book a meeting: https://lnkd.in/dSh2WhAN 🔗 Register here: https://lnkd.in/dnuNZ2D 🔗 Contact us: https://lnkd.in/gcqQbEKp #AurealisTherapeutics #BIOEUROPE #Biotech #Partnering #CellTherapy #GeneTherapy #Investors #Stockholm Maija Rusi Haritha Samaranayake Roger Meier Silvio Inderbitzin Tuomo Pätsi Jean De Gunzburg Igor Mierau Hanna-Riikka Kärkkäinen Jere Kurkipuro Mirka Sanio Jade Jimenez Isoherranen Kirsi Arkadiusz Jawień Joachim Dissemond Valentina Dini Alberto Piaggesi David Armstrong Magdalena Annersten Gershater Jan Apelqvist

Aurealis Therapeutics is proud to sponsor and participate in the 15th Pisa International Diabetic Foot Course 2024, which starts today! 🇮🇹 Our COO, Laurent Decory, will be attending this course, connecting with global leaders and specialists in diabetic foot care—a field closely aligned with our mission. This event focuses on advancing the treatment and management of diabetic foot ulcers (DFUs), one of the key therapeutic areas we are addressing through our innovative 4-in-1 bacterial cell and gene therapy platform. We look forward to engaging with experts in the field and continuing to drive forward innovative solutions for chronic wounds. #AurealisTherapeutics #DiabeticFootUlcers #PisaInternationalFootCourse #ChronicWounds #InnovativeTherapies #Biotech Juha Yrjänheikki Maija Rusi Haritha Samaranayake Roger Meier Silvio Inderbitzin Tuomo Pätsi Jean De Gunzburg Igor Mierau Hanna-Riikka Kärkkäinen Jere Kurkipuro Mirka Sanio Jade Jimenez David Armstrong Alberto Piaggesi Magdalena Annersten Gershater Joachim Dissemond Arkadiusz Jawień Isoherranen Kirsi Valentina Dini

Aurealis Therapeutics is participating the 24th Annual Biotech in Europe Forum starting today in Basel, Switzerland! 📅 This event takes place from 25-26 September 2024 at the Mövenpick Hotel Basel. Our CEO, Juha Yrjänheikki, will engage with investors and partners to explore potential collaboration opportunities. We are proud to be part of this global gathering of leaders in the bio-pharma industry, and we look forward to interesting discussions on investment trends, partnering, and innovation in the life sciences. Let’s meet in Basel! #AurealisTherapeutics #Sachs_BEF #BiotechInEurope #Partnerships #LifeSciences Laurent Decory Haritha Samaranayake Maija Rusi Roger Meier Silvio Inderbitzin Jean De Gunzburg Tuomo Pätsi Igor Mierau Jere Kurkipuro Hanna-Riikka Kärkkäinen Mirka Sanio Jade Jimenez Arkadiusz Jawień David Armstrong Jan Apelqvist Isoherranen Kirsi Joachim Dissemond Alberto Piaggesi Magdalena Annersten Gershater Valentina Dini Sachs Associates

What Laurent likes most about his role as Aurealis Therapeutics COO...   ... is all about driving the company from scientific discovery to commercial readiness and making an impact where it truly matters. 😊 In this video, Laurent discusses the importance of understanding the science behind our multi-target cell & gene therapies, and how creating compelling narratives for investors, Pharma or MedTech companies, clinicians, payers and patients drives him forward.   📰 You can also read the full interview; the link is in the comments section.   #AurealisTherapeutics #TeamInterviews #Biotechnology #LifeSciences #COO Juha Yrjänheikki Maija Rusi Haritha Samaranayake Roger Meier Tuomo Pätsi Silvio Inderbitzin Jean De Gunzburg Igor Mierau Jere Kurkipuro Hanna-Riikka Kärkkäinen Mirka Sanio Jade Jimenez Isoherranen Kirsi Alberto Piaggesi Arkadiusz Jawień Magdalena Annersten Gershater Joachim Dissemond David Armstrong Valentina Dini Jan Apelqvist